Skip to main content

Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · IEX Real-Time Price · USD
12.93
-1.26 (-8.88%)
At close: Dec 3, 2021 4:00 PM
12.95
0.02 (0.15%)
After-hours:Dec 3, 2021 4:00 PM EST
Market Cap344.84M
Revenue (ttm)n/a
Net Income (ttm)-75.44M
Shares Out26.67M
EPS (ttm)-2.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume132,604
Open14.04
Previous Close14.19
Day's Range12.10 - 14.75
52-Week Range12.10 - 27.95
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About XLO

Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. We have built our geographically precise solutions, or GPS, platform to rapidly engineer novel molecules that are designed to optimize their therapeutic index by geographically localizing their activity inside tumors. We are advancing a number of geographically precise, or tumor-selective, agents through various stages of development. Our most advanced product candidat...

IndustryBiotechnology
IPO DateOct 22, 2021
CEORené Russo
Employees66
Stock ExchangeNASDAQ
Ticker SymbolXLO
Full Company Profile

Financial Performance

Financial Statements

News

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022

2 days ago - GlobeNewsWire

Xilio Therapeutics Announces Closing of Initial Public Offering

WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced ...

1 month ago - GlobeNewsWire

Xilio Therapeutics Announces Pricing of Initial Public Offering

Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced the pricing of its initial public offering of 7,35...

1 month ago - Business Wire

Xilio Therapeutics IPO Registration Document (S-1)

Xilio Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC